Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Oral 17-Alpha-Alkylated Steroids & Hepatotoxicity

The Chemistry of Why Oral Steroids Harm the Liver

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Applies to multiple Schedule III oral AAS (e.g., stanozolol, oxymetholone, methandrostenolone, oxandrolone)
WADA
The affected oral steroids are Prohibited at all times (S1 Anabolic Agents).

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about oral 17-alpha-alkylated steroids & hepatotoxicity in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Most oral anabolic steroids share a single structural feature: a methyl or ethyl group added at the 17-alpha position. This 17-alpha-alkylation blocks rapid hepatic first-pass breakdown, making the steroid orally bioavailable, but the same metabolic resistance burdens the liver. 17aa orals are associated with elevated transaminases, cholestasis (impaired bile flow), peliosis hepatis (blood-filled hepatic cysts), and, with prolonged use, hepatocellular adenomas and carcinoma. They also disproportionately suppress HDL cholesterol. Crucially, this toxicity is a property of the molecule, not the route, so injectable 17aa steroids (e.g., injectable stanozolol) remain hepatotoxic.

One small chemical modification makes a steroid oral, and toxic to the liver.

What it is invoked to explain

Claims this idea is used to support. Whether it supports them is the rest of the entry.

  • Documentary explanation of oral-steroid hepatotoxicity across the AAS class
Educational/harm-reduction topic
Explains why orals require liver monitoring and why 'oral cycles' carry distinctive hepatic risk.

How it is supposed to work

An alkyl group at carbon-17-alpha sterically hinders the hepatic enzymes that would otherwise rapidly conjugate and inactivate the steroid, allowing oral absorption to reach the systemic circulation. The trade-off is prolonged hepatic exposure and interference with bile transport, producing cholestasis; oxidative and vascular injury can lead to peliosis hepatis and neoplasia. 17aa steroids also strongly induce hepatic lipase and suppress HDL.

The shared culprit is the carbon-17-alpha methyl (or ethyl) substituent. Non-17aa orals that use alternative strategies (e.g., 1-methylation in methenolone and mesterolone) are comparatively less hepatotoxic, underscoring that the 17aa group specifically drives the liver risk.

Route does not equal safety

A persistent myth holds that injecting a steroid spares the liver. For 17aa compounds this is false: the hepatotoxic group travels with the molecule regardless of administration route, so injectable stanozolol is still hepatotoxic. Conversely, non-alkylated injectables (testosterone esters, nandrolone) are not primarily hepatotoxic, the difference is chemistry, not needles.

Safety in detail

This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Oral 17aa steroids carry documented hepatic risks; self-administration without monitoring is hazardous.

  • Elevated transaminases and cholestatic jaundice.
  • Peliosis hepatis (blood-filled hepatic cysts), which can rupture.
  • Hepatocellular adenoma and carcinoma with prolonged use.
  • Disproportionate HDL suppression (cardiovascular relevance).
  • Route-independent: injectable 17aa steroids are still hepatotoxic.

Replacement is not the same as a cycle

Hepatic risk scales with dose and duration of 17aa exposure. Supraphysiological physique use, high doses, stacked orals, prolonged cycles, magnifies it. This entry explains mechanism; it provides no dosing.

What it does to fertility

Like all AAS, 17aa orals suppress LH/FSH and spermatogenesis; the hepatotoxicity discussed here is additional to, not a substitute for, the fertility and cardiovascular harms of the class.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Liver function (AST/ALT, bilirubin, GGT)
  • Hepatic imaging if symptomatic
  • Lipid panel
  • LH/FSH, testosterone

What people get wrong

  • Often said'Injectable steroids are easier on the liver, so injectable Winstrol is safe'

    ActuallyHepatotoxicity tracks the 17-alpha-alkyl group, not the route. Injectable 17aa steroids remain hepatotoxic; the protection comes from avoiding the alkyl group, not from injecting.

  • Often said'Liver values normalize after stopping, so it does no real harm'

    ActuallyTransaminases often recover, but peliosis hepatis and hepatic tumors are structural lesions that can persist and, rarely, prove fatal.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

17-alpha-alkylation was developed in the 1930s-50s to make orally active androgens and estrogens (the same trick underlies orally active synthetic hormones). As oral AAS proliferated mid-century, hepatic complications, cholestatic jaundice, then peliosis hepatis and tumors, were progressively documented in patients and athletes, establishing the class warning that persists today.

  1. 1930s-50s17-alpha-alkylation developed for oral hormone activity
  2. 1960s-70sCholestatic jaundice reported with oral AAS
  3. 1970s-80sPeliosis hepatis and hepatic tumors linked to 17aa steroids
  4. PresentStandardized class hepatotoxicity warnings; basis for liver monitoring

At a glance

Modification
17-alpha-alkyl (methyl/ethyl) group
Purpose
Oral bioavailability (resists first-pass metabolism)
Liver lesions
Cholestasis, peliosis hepatis, adenoma/carcinoma
Lipid effect
Disproportionate HDL suppression

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Oral 17-Alpha-Alkylated Steroids & Hepatotoxicity. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • LiverTox (NIH) monographs on anabolic steroidsongoing

    Catalog cholestatic injury, peliosis hepatis and hepatic tumors associated with 17aa AAS.

  • Case series of peliosis hepatis and hepatocellular tumors in AAS usersvarious

    Document serious, occasionally fatal hepatic lesions linked to prolonged 17aa use.

  • Pope et al., Endocrine Society Scientific Statement2014

    Summarizes hepatic and lipid harms of oral 17aa steroids within the class.